01
GIP
GIP participates in nutrient response and glucose-dependent insulin signalling.
GIP/GLP-1 receptor dual agonist
Tirzepatide
GIP · GLP-1
Tirzepatide is a long-acting dual agonist with registered medicines for type 2 diabetes and chronic weight management in defined populations. Registered pens have controlled formulation and titration; research vials are not equivalent.
2Overview
1× / wkReference frequency
DataLarge phase 3 and outcomes trials
Research status
Approved for specific diabetes and obesity indications
TIRZEPATIDE10 MG
01 · Overview
What is Tirzepatide?
Tirzepatide is a long-acting dual agonist with registered medicines for type 2 diabetes and chronic weight management in defined populations. Registered pens have controlled formulation and titration; research vials are not equivalent.
Research route, formulation and population determine what a result actually means.
02
GLP-1
GLP-1 signalling affects satiety, gastric emptying and glucose-dependent insulin response.
02 · Research
What do the studies show?
Large phase 3 and outcomes trials. Educational information. Not diagnosis, treatment or use advice.
20.9%
Phase 3SURMOUNT-1
In 2,539 adults, mean weight change at 72 weeks was −20.9% with 15 mg versus −3.1% with placebo.
Weekly
Approved active substanceGlycaemia and weight
SURPASS and SURMOUNT programmes support efficacy; gastrointestinal effects, gallbladder risks and contraindications remain important.
03 · DATA
Peptide and product specifications
Checked identity data for this research compound or blend.
TirzepatidePeptide and product specifications
Development code
LY3298176
Developer
Eli Lilly and Company
Molecular formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight
4813.53 Da
CAS number
2023788-19-2
Amino-acid sequence / components
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA₂-γGlu-C20-diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Amino-acid count
39
Modified residues
Aib at positions 2 and 13; C20 fatty-diacid linker at Lys²⁰; C-terminal serinamide
Pharmacokinetic half-life
Approximately 5 days for the registered medicine
Purity
Batch-specific — confirm identity and purity with the Velora COA
Reference diluent
Registered tirzepatide medicines are ready-made formulations; a research vial is not equivalent
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data
These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.
Official FDA prescribing information ↗04 · Calculator
Reconstitution and U-100 conversion
This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.
Calculator
Once weekly for registered products
1
2
3
4
Draw to
0 units
0.00 mL
TIRZEPATIDE
10 MG
Concentration—
Per unit—
Complete amounts—
Calculated duration—
LAB · RECONSTITUTION
How to reconstitute Tirzepatide for laboratory research
A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.
Clean
Disinfect the rubber closures of both vials and allow them to dry.
Measure diluent
Withdraw only the diluent validated for the specific compound.
Add slowly
Let the liquid run slowly down the inside wall of the vial.
Swirl gently
Do not shake; rotate gently until the material has dissolved.
Store per protocol
Follow the product label, COA and validated stability data.
Important checks before and after reconstitution
Check the product
First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.
Use clean, sterile technique
Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.
Concentration, not total amount
The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.
Inspect and label
Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.
General reconstitution volumes listed by the source
General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.
| Vial strength | Commonly listed volume |
|---|---|
| 2 mg | 1–2 mL |
| 5 mg | 2–3 mL |
| 6 mg | 2–3 mL |
| 10 mg | 2–4 mL |
| 15 mg | 3–5 mL |
| 20 mg | 4–8 mL |
Practical background source: Free Medical Journals — Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.
05 · Safety and limitations
Safety and limitations
Research route, formulation and population determine what a result actually means.
What is known
- Visible research claims use primary or official sources.
- The calculator is arithmetic and does not turn a study amount into medical advice.
- A registered medicine and a research vial are not automatically equivalent.
What remains uncertain
- Many products lack long-term safety data and independent replication.
- Animal and cell findings do not predict a safe human dose.
- Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Approved for specific diabetes and obesity indications. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ
Frequently asked questions
Tirzepatide is a long-acting dual agonist with registered medicines for type 2 diabetes and chronic weight management in defined populations. Registered pens have controlled formulation and titration; research vials are not equivalent.
In 2,539 adults, mean weight change at 72 weeks was −20.9% with 15 mg versus −3.1% with placebo. SURPASS and SURMOUNT programmes support efficacy; gastrointestinal effects, gallbladder risks and contraindications remain important.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
Measured after reconstitution with 0.9% bacteriostatic water at approximately 2 °C. The method and small sample make this directional, not a pharmaceutical shelf-life validation.
2–8 °C. Protect from light and repeated freeze-thaw cycles.
07 · Sources
Primary research sources
Educational information. Not diagnosis, treatment or use advice.